Pediatric AML and No Matched Donor: What Families Should Know About Haploidentical Transplant
For parents, caregivers, and referring physicians when a child with acute myeloid leukemia needs a transplant and a full HLA match has not been found.
When a child's AML team recommends bone marrow transplant and no fully matched donor is available, a parent can usually be evaluated as a haploidentical, or half-matched, donor. International families and referring physicians do not need to finish a long unrelated-donor search before asking whether that pathway fits. In China, haploidentical donors are a common source for pediatric transplants, and remote review can start from records already in hand.
Key point for families and referring physicians:
This page starts after transplant has been raised for a child with AML. A biological parent is almost always a half-match. At experienced centres, that parent can be worked up alongside any registry search, which matters because pediatric AML often cannot wait several months in remission. ChinaMed Waypoint coordinates records and communication; the transplant decision stays with the hematology team.
This page sits in ChinaMed Waypoint's haploidentical transplant resources for international families facing no matched donor, a parent-donor question, or transplant review in China. The child's disease context also belongs with pediatric leukemia and blood disorders. Children whose AML is still being treated with chemotherapy alone, including many with favourable-risk disease or acute promyelocytic leukemia, should start with AML treatment options explained rather than this donor guide.
What a half-matched donor means in pediatric AML
A full match usually means a sibling or unrelated donor who matches the child at the main HLA genes used for transplant, often described as 10/10 or 8/8. A haploidentical donor shares one HLA haplotype — about half the tissue type. Every biological parent is a haploidentical donor for their child. A sibling may be a full match, a half-match, or neither.
In pediatric AML, that fact changes the search. The question is not whether any donor exists in the family. A parent is already there. The question is whether the child's disease status, the parent's medical fitness, and the centre's graft-versus-host disease (GVHD) prevention plan make that donation an appropriate next step.
Adult AML without a full match is covered separately in AML options when no full HLA match is available. Donor strategy across childhood blood diseases, not only AML, is outlined in what if my child has no matched donor.
Why the remission window matters more than a perfect registry match
Allogeneic transplant for AML is generally planned in remission, often first complete remission for higher-risk disease or second remission after relapse. Remission can be lost while a family waits. An international unrelated-donor search — typing, confirmation, donor clearance, and collection — commonly takes months. A parent who is already identified can be typed, counselled, and medically cleared on a shorter clock.
That does not mean every family should abandon a registry search. Matched sibling donors, when they exist, remain a standard first look. A matched unrelated donor may still be preferred in some protocols. The practical point for pediatric AML is parallel work: family HLA typing and registry search at the same time, with a date by which the team will choose a donor if the child is ready.
Timing questions to settle with the current team
- Is transplant recommended in this remission, or only if disease returns?
- How long can this child safely stay in remission while a donor is sought?
- Have both parents, and full siblings, already been HLA typed?
- Is the unrelated-donor search running at the same time as family typing?
- What disease status is required before conditioning can start?
How a parent-donor workup actually proceeds
HLA typing confirms the half-match and looks for antibodies in the child that might react against the parent's tissue type. The parent then has a donor medical exam: blood counts, infectious-disease testing, heart and lung fitness, and a check that donation itself is safe. Either peripheral-blood stem cells or bone marrow may be collected, depending on the protocol. The parent is a donor, not a patient, but collection is still a medical procedure.
Teams sometimes prefer one parent over the other because of age, medical history, the child's HLA antibodies, cytomegalovirus status, or the number of mismatched HLA genes in the graft-versus-host direction. Families should expect that preference to be explained, not guessed. A plain-language account of parent donation is in can parents become bone marrow donors for their child. Published pediatric risk context is in is haploidentical transplant safe for children.
What the weeks in hospital feel like — conditioning, engraftment, infection risk, and GVHD — is covered in what families should know before a child's bone marrow transplant. This page stays on the donor decision.
What hematologists weigh before choosing a haploidentical donor
Donor type is never the only variable. For a child with AML, the team usually looks at remission and measurable residual disease, cytogenetics and mutations, how many courses were needed to get there, prior toxicity, infection, and whether a matched sibling exists. High-risk features and persistent residual disease are common reasons transplant is discussed in first remission. Favourable-risk AML and acute promyelocytic leukemia often follow a different path; if that is the diagnosis, confirm with the current hematologist before planning travel.
Transplant from any donor, including a parent, is more often planned when leukemia is in remission. If the child is not in remission, the next step is usually further treatment to reduce disease, not an immediate flight. A remote review can still say whether a haploidentical workup should start in parallel.
Why a B-ALL plan, including CD19 CAR-T, does not transfer to AML
Families who have read about childhood leukemia online often meet CAR-T first. Commercial CD19 CAR-T is built for B-cell acute lymphoblastic leukemia. It does not treat AML. If friends or another hospital suggested CAR-T because “there is no donor,” that suggestion needs to be checked against the actual diagnosis.
The contrast with pediatric ALL pathways is in ALL treatment options for adults and children. Cell therapy more broadly is indexed under CAR-T and cell therapy in China. If AML returns after a transplant, later choices such as donor lymphocyte infusion or a second transplant are discussed in options if leukemia comes back after transplant.
What international families ask about haploidentical transplant in China
Chinese pediatric transplant practice uses haploidentical family donors as a routine donor source, not only as a last resort. In the CCBMTR nationwide registry of 22,381 pediatric transplants from 2017 to 2024, haploidentical donors accounted for about 56 percent of cases, and AML was among the leading indications alongside ALL, aplastic anemia, and thalassemia major. The dataset is summarised in what 22,381 pediatric transplants show about practice in China.
One widely published approach is the Beijing Protocol, developed at Peking University Institute of Hematology, using intensified GVHD prevention that includes anti-thymocyte globulin. Other centres use post-transplant cyclophosphamide. Neither label tells a family whether their child should proceed. It tells them to ask which platform the centre uses, how many children with similar AML they have transplanted, and what they quote for GVHD, graft failure, and relapse in that group. Background on the protocol is in Beijing Protocol evidence for international patients.
Registry percentages are not a personal prognosis. A child with residual disease, infant AML, or major organ damage is not described by a national average. The useful China-specific question is narrower: if no full match exists and the home team has already advised transplant, can a parent-donor plan be reviewed from the records before anyone travels? That review is requested through online MDT consultation. Practical coordination after a team accepts the case sits with cancer treatment coordination in China and the haploidentical transplant coordination service.
Records that make a pediatric AML donor review possible
A centre cannot judge a parent-donor plan from a diagnosis label alone. International families usually need to assemble:
- Pathology and the latest bone marrow report, with the date
- Chromosome results and the molecular or NGS panel, including FLT3 and other markers the home team used for risk
- Measurable residual disease results, and the method used
- A treatment list: drugs, dates, responses, and any induction failure
- Current blood counts, organ function, and major infections
- HLA reports for the child and anyone already typed, especially both parents and full siblings
- A short letter from the current pediatric hematologist stating why transplant is recommended now
Incomplete typing is common. If parents have never been tested, say so. A review can still advise whether family typing should be the first action at home.
Supportive care in China alongside transplant, not instead of it
A haploidentical transplant for pediatric AML is intensive hematology care: conditioning chemotherapy, a period with almost no immune system, and months of infection and GVHD precautions. Supportive care sits beside that plan. It does not replace the transplant, and it does not replace chemotherapy used to reach remission.
Families staying in China for the early months often need practical help with food safety, appetite, sleep, and caregiver fatigue. Nutrition limits during and after pediatric transplant are set out in the pediatric HSCT dietary safety guide. Where a hospital team agrees, integrative support such as acupuncture or other Traditional Chinese Medicine approaches may be used for symptoms. Those approaches are complementary. Herbs and supplements should be reviewed by the transplant physicians before use, because they can interact with conditioning drugs and immunosuppression. A broader explanation is in how supportive care helps during cancer treatment.
Frequently Asked Questions
Can a child with AML have a transplant without a fully matched donor?
Yes, if the treating team has already recommended allogeneic transplant. A haploidentical family donor — most often a parent — is an established option when no matched sibling or matched unrelated donor is available. Suitability still depends on the child’s remission status, risk group, organ function, and the centre’s protocol.
Can a parent donate bone marrow or stem cells to a child with AML?
A biological parent is, by HLA inheritance, a half-match for their child and can usually be typed and medically cleared as a haploidentical donor. Which parent is preferred, and whether a sibling is a better half-match, is a clinical decision. Donation requires its own health evaluation and is not automatic.
Should families wait for an unrelated donor search to finish before considering a parent donor?
In pediatric AML, the remission window can be short. Many transplant teams type family donors in parallel with a registry search, rather than waiting months for a 10/10 unrelated donor that may never appear. Waiting is sometimes reasonable; it should be an explicit decision with the child’s hematologist, not the default.
Does CAR-T replace transplant for a child with AML who has no matched donor?
No. CD19 CAR-T used for relapsed B-cell acute lymphoblastic leukemia does not treat AML. If transplant has been recommended for pediatric AML, lack of a full match points toward an alternative donor — often a haploidentical parent — not toward a B-ALL CAR-T product.
What records are needed before a remote AML transplant review in China?
Useful packets include the diagnosis and latest bone marrow report, cytogenetics and molecular results, measurable residual disease if tested, a treatment summary with dates and responses, current blood counts and organ-function tests, infection history, and any HLA typing already done on the child and parents. ChinaMed Waypoint can organise these for specialist review; the review itself is done by the hospital team.
Medical Disclaimer: ChinaMed Waypoint is a coordination service, not a medical provider. Nothing in this article constitutes medical advice. All treatment decisions should be made in consultation with a qualified oncologist, hematologist, transplant physician, or relevant specialist.
Request a Structured Pediatric Hematology Case Review
If your child with AML has been advised to have a transplant and no full match has been found, a remote review can look at whether a parent donor should be worked up before any travel decision.
Request a Case Review